Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial.
Int J CancerJun 9, 2026 (epub)
Jurek Hille, Sylvie Lorenzen, Claudia Pauligk et al.
✦ AI-curated · Sources linked
In 30 seconds
This exploratory biomarker analysis from the phase II RAMIRIS trial evaluated plasma placental growth factor (PlGF) in 99 patients with advanced gastroesophageal adenocarcinoma receiving ramucirumab-based therapy. Elevated PlGF levels at baseline and early treatment were associated with shorter overall survival (OS), with a multivariate hazard ratio of 1.85 (p=0.030) at Cycle 2 Day 1.
Key findings
- Elevated baseline PlGF levels were associated with shorter OS (HR u = 1.75; p = 0.020).
- PlGF levels increased substantially during treatment, while CAIX showed a transient rise.
- At Cycle 2 Day 1, elevated PlGF was linked to shorter OS (HR m = 1.85; p = 0.030).
- CAIX and tryptase did not show consistent associations with survival.
Why it matters
Identifying reliable biomarkers like PlGF could enhance prognostic assessments and treatment strategies in advanced gastroesophageal adenocarcinoma, potentially guiding therapeutic decisions in clinical practice.